偏头痛是一种常见病,多数于青春期起病,症状及复发作,可连续多年,影响病人的正常生活和工作。以往对偏头痛急性发作的治疗,或用镇痛剂,或用麦角胺类药物,但前者疗效欠佳,后者则副反应大,长期应用还会产生药物依赖性。近年来Glaxo制药集团合成了一种选择性作用于5HT_1受体的药物Sumatriptan(商品名:英明格,Imigran,为Sumatriptan的琥珀酸盐),经上海、北京等医院临床,证明 Migraine is a common disease, most onset in adolescence, symptoms and recurrence for many years, affecting the normal life of patients and work. In the past the treatment of acute migraine attacks, or the use of analgesics, or ergotamine drugs, but the former poor efficacy, the latter side effects, long-term use will produce drug dependence. In recent years, Glaxo Pharmaceuticals has synthesized a Sumatriptan (trade name: Imigran, a Sumatriptan succinate) selective for the 5HT 1 receptor, which has been clinically proven in Shanghai and Beijing hospitals